CN109568269A - One kind having the function of diagnosis and treatment excretion body and preparation method thereof - Google Patents
One kind having the function of diagnosis and treatment excretion body and preparation method thereof Download PDFInfo
- Publication number
- CN109568269A CN109568269A CN201811222290.9A CN201811222290A CN109568269A CN 109568269 A CN109568269 A CN 109568269A CN 201811222290 A CN201811222290 A CN 201811222290A CN 109568269 A CN109568269 A CN 109568269A
- Authority
- CN
- China
- Prior art keywords
- excretion body
- diagnosis
- sample
- treatment
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000029142 excretion Effects 0.000 title claims abstract description 104
- 238000003745 diagnosis Methods 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 86
- 239000004148 curcumin Substances 0.000 claims abstract description 43
- 229940109262 curcumin Drugs 0.000 claims abstract description 43
- 235000012754 curcumin Nutrition 0.000 claims abstract description 43
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 43
- 238000004520 electroporation Methods 0.000 claims abstract description 26
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 26
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- 230000005611 electricity Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 210000000130 stem cell Anatomy 0.000 claims abstract description 6
- 238000004113 cell culture Methods 0.000 claims abstract description 5
- 238000011534 incubation Methods 0.000 claims abstract description 3
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 7
- 230000003252 repetitive effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 2
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 29
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 16
- 235000017491 Bambusa tulda Nutrition 0.000 description 16
- 241001330002 Bambuseae Species 0.000 description 16
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 16
- 239000011425 bamboo Substances 0.000 description 16
- 150000002475 indoles Chemical class 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000005199 ultracentrifugation Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000007626 photothermal therapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention discloses one kind to have the function of diagnosis and treatment excretion body and preparation method thereof, belongs to nanosecond medical science technical field.This method comprises: 1) excretion body is extracted, is purified: filling in interstital stem cell culture solution the excretion body for extracting cell secretion from C57 mouse, obtained excretion weight is suspended from 10mM PBS solution, and -80 DEG C save backup；2) sample preparation: the excretion body of the curcumin prepared or indocyanine green solution and step 1) is mixed in 10mM PBS, sample is obtained；3) electricity turns: the sample of step 2) being carried out electroporation, the sample after obtaining electroporation；4) it is incubated for: the sample of step 3) electroporation being placed in cell incubator and is protected from light incubation 30min, the liquid after being incubated for；5) it purifies: the liquid after being incubated in step 4) being centrifuged 60-100min, taking precipitate obtains having the function of diagnosis and treatment excretion body.Operation of the present invention is simple, and repetitive rate is high.
Description
Technical field
The invention belongs to nanosecond medical science technical fields, in particular to a kind of to have the function of diagnosis and treatment excretion body and its preparation side
Method.
Background technique
Chemotherapy is still one of major way of oncotherapy.But there are poorly water-soluble, metabolism for most of chemotherapeutics fastly,
Poor biocompatibility is distributed the undesirable defects such as low with Premeabilisation of cells ability in vivo, seriously limit chemotherapeutics effect and
Utilization rate.Therefore, a kind of novel pharmaceutical carrier is constructed, to improve drug solubility and stability, penetration into tissue is improved, mentions
High tumor locus drug concentration, while avoiding being captured by immunocyte is current research hot spot.
Unique advantage of the excretion body in medicament transport, becomes one of research hotspot.Excretion body is by mammal
Cell-derived nano vesicle, diameter is probably in 40-200nm or so.Excretion body can be identified as " itself " by host, therefore its
As a kind of active carrier, the substances such as certain cell RNAs, drug molecule can be delivered in mammalian cell.This seed capsules
Blister corpusculum has unique advantage as carrier, and if its immunogenicity is low, stability in blood is high, transports medicine to cell
High-efficient and stronger enhancing infiltration retention effect of object etc..Currently, existing research person utilizes excretion body carrying medicament, as a result table
It is bright compared with free drug, excretion body carrying medicament have better anti-tumor activity.But excretion body carrying medicament efficiency compared with
Low, patent CN108114290A discloses the preparation method of excretion body that is a kind of while loading chemicals and nano material, uses
Curcumin and nano ferriferrous oxide are loaded into excretion body by electric shifting method, but full text does not have table for excretion body encapsulation rate
It states.Excretion physical efficiency is enough in the load of a variety of different type drugs, including nucleic acid molecules (mRNA, siRNA etc.), chemicals
(curcumin, indocyanine green etc.) and nano material (nano silver, Nanoscale Iron etc.).
Curcumin is a kind of fat-soluble phenolic substances extracted from Zingiber curcuma turmeric rhizome, is contained in structure
There is phenolic hydroxyl group, when peroxidatic reaction of lipid occurs for cell membrane, oxidation reaction can occur for phenolic hydroxyl group, can effectively terminate freedom
Base reaction, thus it shows many physiological activity, such as anti-oxidant, antitumor, many effects such as prevent aging.Experiment in vitro
Show that curcumin can significantly inhibit proliferation, migration and the invasion of tumour cell, and promotes apoptosis of tumor cells.Therefore, turmeric
Element has broad application prospects in kinds cancer.Indocyanine green (ICG) is currently the only a kind of by the close of U.S. FDA certification
Infrared (NIR) dyestuff.Studies have shown that ICG has photodynamic properties, can be generated after capable of being excited by the NIR light of strong penetrating power
Active oxygen.And then tumor locus can be cooperated with by photo-thermal therapy and oxyradical, reach and kills tumour cell
Effect.Therefore, ICG is to be presently considered in photo-thermal therapy most promising drug.
Traditional oncotherapy can only be by Drug inhibition tumour growth, and the diagnosis and the state of an illness for inside tumor are evaluated
It is not prompt enough, accurate.We turn parameter and drug quality ratio by inquiring into different electricity, provide a kind of efficiently preparation and have and examine
The excretion body method for treating integrated function, drug is rapidly and efficiently contained inside excretion body, while can be used in a variety of drugs
Combination contains, and realizes the concertedness and consistency of oncotherapy and diagnosis.
Summary of the invention
The primary purpose of the present invention is that overcome presently, there are technological deficiency, providing a kind of has the function of diagnosis and treatment excretion body
Preparation method.This method is easy to operate, repetitive rate is high.Excretion body obtained encapsulation rate with higher and diagnosis and treatment integration function
Can, can be suitable for a variety of single medicines contain and the total load of multiple combinations drug.The excretion body tool that this method is prepared
There are the functions such as chemotherapy, photo-thermal therapy, photodynamic therapy and imaging, the diagnosing and treating for a variety of diseases such as tumour provides one
The new carrier and preparation method thereof of kind.
Another object of the present invention is to provide what is obtained by above-mentioned preparation method to have the function of diagnosis and treatment excretion body.
The purpose of the invention is achieved by the following technical solution:
A kind of preparation method with diagnosis and treatment excretion body, includes the following steps:
1) excretion body is extracted, is purified: being filled in interstital stem cell culture solution and is extracted from C57 mouse using differential supercentrifugation
The excretion body of cell secretion, obtained excretion weight are suspended from 10mM PBS solution, and -80 DEG C save backup；
2) the excretion body of the curcumin prepared or indocyanine green solution and step 1) sample preparation: is mixed in 10mM PBS
In, it is uniformly mixed, obtains sample；
3) electricity turns: the sample of step 2) is placed in electroporation apparatus and carries out electroporation, the sample after obtaining electroporation；
4) it is incubated for: the sample of step 3) electroporation being placed in cell incubator and is protected from light incubation 30min, after being incubated for
Liquid；
5) it purifies: by the liquid after being incubated in step 4) with 100,000-140,000g centrifugal force 60-100min, taking
Sediment obtains having the function of diagnosis and treatment excretion body.
In one of them embodiment, the C57 mouse does not fill interstital stem cell culture solution for no excretion body serum or not
Containing serum.
In one of them embodiment, in step 2), 0-100 μ g is separately added into 10mM PBS solution described in 200 μ L
Excretion body, 0-300 μ g curcumin or 0-300 μ g indocyanine green.
In one of them embodiment, in step 3), the condition of electroporation are as follows: voltage 0-350V, 100 μ s of pulsewidth,
Every 1000 μ s, discharge time: 0-9 times.
One kind having the function of diagnosis and treatment excretion body, is obtained by above-mentioned preparation method.What is be prepared has the function of diagnosis and treatment excretion
Body has medicament slow release performance.
The present invention has the following advantages and effects with respect to the prior art:
(1) preparation method of the invention operation is simple, and preparation time is short, and repetitive rate is high.What is be prepared has diagnosis and treatment function
Energy excretion body has medicament slow release performance, and encapsulation rate is up to 90%；Its solubility that can be improved hydrophobic drug, stability
And permeability, it avoids being swallowed and being removed by immune system in the living body.
(2) what is be prepared has the function of that diagnosis and treatment excretion body is able to maintain complete nano vesicle structure and mobility, together
When remain the physico-chemical property of carrying medicament, such as chemotherapeutic activity, photo-thermal effect, photodynamic effect and fluorescence imaging effect,
Realize diagnosis and treatment integration.
Detailed description of the invention
Fig. 1 is that the excitation of qualitative and quantitative detection near infrared light has the function of the fluorogram that diagnosis and treatment excretion body generates, in which: A
For excretion body, B be curcumin, C is indocyanine green, D is curcumin and indocyanine green；
Fig. 2 is the encapsulation rate result figure with diagnosis and treatment excretion body, in which: A is that excretion body carries curcumin, B is excretion
Body carries that the indoles mountain valley with clumps of trees and bamboo is green, C is that excretion body carries curcumin and the indoles mountain valley with clumps of trees and bamboo is green, D is that excretion body carries curcumin and the indoles mountain valley with clumps of trees and bamboo is green；
Fig. 3 is the testing result figure with the average grain diameter of diagnosis and treatment excretion body, in which: A is excretion body, B is that electricity turns
Excretion body, C are that carry curcumin, D be that excretion body carries that the indoles mountain valley with clumps of trees and bamboo is green, E is that excretion body carries curcumin and the indoles mountain valley with clumps of trees and bamboo is green to excretion body；
Fig. 4 is the testing result figure with the average potential of diagnosis and treatment excretion body, in which: A is excretion body, B is that electricity turns
Excretion body, C are that carry curcumin, D be that excretion body carries that the indoles mountain valley with clumps of trees and bamboo is green, E is that excretion body carries curcumin and the indoles mountain valley with clumps of trees and bamboo is green to excretion body；
Fig. 5 be vitro detection have the function of the testing result figure of the photo-thermal effect of diagnosis and treatment excretion body, in which: A be phosphate,
B is curcumin, C is that the indoles mountain valley with clumps of trees and bamboo is green, D is curcumin and the indoles mountain valley with clumps of trees and bamboo is green, E is excretion body, F is that excretion body carries curcumin, G is excretion
The body load indoles mountain valley with clumps of trees and bamboo is green, H is that excretion body carries curcumin and the indoles mountain valley with clumps of trees and bamboo is green；
Fig. 6 is the testing result figure with diagnosis and treatment excretion body cumulative in vitro drug release, in which: A is curcumin, B
For the indoles mountain valley with clumps of trees and bamboo is green, C is that excretion body carries curcumin, D is that excretion body carries that the indoles mountain valley with clumps of trees and bamboo is green, E is to carry curcumin and the green (turmeric of the indoles mountain valley with clumps of trees and bamboo
Element), F be excretion body carry curcumin and the indoles mountain valley with clumps of trees and bamboo it is green (the indoles mountain valley with clumps of trees and bamboo is green).
Specific embodiment
Below with reference to embodiment, the present invention is described in further detail, and embodiments of the present invention are not limited thereto.
In this application, it separates first, purify excretion body:
1) excretion body is extracted, is purified: it collects C57 mouse and fills interstital stem cell supernatant 200mL progress differential centrifugation:
300g, 10min take supernatant；2,000g, 10min take supernatant；10,000g, 30min take supernatant；100,000g, 70min are resuspended heavy
It forms sediment；100,000g, 70min are resuspended in 200 μ L 10mM PBS, and 30 μ L samples is taken to measure protein content for BCA；
2) curcumin solution is prepared: weighing 4mg curcumin powder, 200 μ L DMSO solutions are added, mixes well, uses 10mM
PBS adds to 1mL, is configured to 2mg/mL curcumin solution；
3) indocyanine green solution is prepared: weighing 4mg indocyanine green powder, 200 μ L DMSO solutions are added, mix well, use
10mM PBS adds to 1mL, is configured to 2mg/mL indocyanine green solution；
Then the drugs such as curcumin, indocyanine green are loaded by excretion body by electroporation again:
4) electricity turns: excretion body, curcumin solution, indocyanine green solution is added by a certain percentage in 10mM PBS solution；
It after mixing, is added in 96 porocyte culture plates, is put into electroporation apparatus, carry out electroporation according to certain reaction condition；
5) it is incubated for: 96 orifice plates being protected from light after perforation and are put into 37 DEG C of incubators, be incubated for 30min；
6) purify: twice through 100,000-140,000g ultracentrifugation, each 70-90min is gone the excretion body after perforation
Clearly, sediment is to have the function of diagnosis and treatment excretion body (the excretion body of carrying medicament)；
7) fluorescence detection: by step 6) have the function of that diagnosis and treatment excretion body takes 10 μ L to be diluted to 100 μ L with 10mM PBS after
It is added drop-wise on phosphorimager, detects 700nm, 800nm fluorescent absorption value respectively；
8) Uv-vis is detected: step 6) is had the function of that diagnosis and treatment excretion body ultraviolet-visible spectrophotometer is distinguished
In 421nm detection curcumin, 784nm detection indocyanine green absorption value, and and standard curve control, computational envelope rate；
9) partial size and potentiometric analysis: take step 6) has the function of that diagnosis and treatment excretion body carries out partial size and potentiometric analysis, detection
Particle diameter distribution and current potential；
10) photo-thermal effect: step 6) is had the function of that diagnosis and treatment excretion body is added in 3mL silica dish, is swashed with 808nm is infrared
Light device radiates 5min, and every 30s records temperature change；
11) medicament slow release: take step 6) has the function of that diagnosis and treatment excretion body carries out cumulative in vitro release, calculates medicament slow release
Efficiency.
Embodiment 1
80 μ g excretion bodies are added in 10mM PBS solution, is added to after mixing in 96 orifice plates, is put into electroporation apparatus, according to
Following parameter manipulation: voltage 250V, 100 μ s of pulsewidth, 1000 μ s of interval, discharge time 6 times.Suspension can be put after electroporation
Enter and be incubated for 30min in cell incubator, then 100,000g ultracentrifugation twice, 70min/ times, removes supernatant, with 200 μ L PBS
Precipitating, the excretion body after obtaining electroporation is resuspended.Its partial size is~150nm, as shown in Figure 3.Zeta potential is~-8mV, is such as schemed
Shown in 4.4 DEG C are protected from light storage and carry out subsequent detection and experiment.
Embodiment 2
80 μ g excretion bodies and 80 μ L curcumin solution (concentration 2mg/mL) are added in 10mM PBS solution, add after mixing
Enter into 96 orifice plates, be put into electroporation apparatus, according to following parameter manipulation: voltage 250V, 100 μ s of pulsewidth are spaced 1000 μ s, electric discharge
Number 6 times.Suspension can be put into cell incubator after electroporation and be incubated for 30min, then 100,000g ultracentrifugation two
It is secondary, 70min/ times, supernatant is removed, it is the excretion body for loading curcumin that precipitating, which is resuspended, with 200 μ L PBS.Its encapsulation rate be~
86.64%, as shown in Figure 2；Its partial size is~170nm, as shown in Figure 3；Zeta potential is~-17mV, as shown in Figure 4；Preparation
The excretion body of obtained load curcumin has medicament slow release performance, as shown in Figure 6.4 DEG C be protected from light storage carry out subsequent detection and
Experiment.
Embodiment 3
80 μ g excretion bodies and 40 μ L indocyanine green solution (concentration 2mg/mL) are added in 10mM PBS solution, after mixing
It is added in 96 orifice plates, is put into electroporation apparatus, according to following parameter manipulation: voltage 250V, 100 μ s of pulsewidth are spaced 1000 μ s, put
Electric number 6 times.Suspension can be put into cell incubator after electroporation and be incubated for 30min, then 100,000g ultracentrifugation
Twice, 70min/ times, remove supernatant, with 200 μ L PBS be resuspended precipitating be load indocyanine green excretion body, encapsulation rate be~
97.79%, as shown in Figure 2；Partial size is~180nm, as shown in Figure 3；Zeta potential is~-6mV, as shown in Figure 4.It is prepared
The excretion body of load indocyanine green have fluorescence imaging, photo-thermal effect and medicament slow release performance, such as Fig. 1, shown in 5,6.4 DEG C are kept away
Light storage carries out subsequent detection and experiment.
Embodiment 4
80 μ g excretion bodies and 40 μ L curcumin solution (concentration 2mg/mL) and 40 μ L are added in 10mM PBS solution
Indocyanine green solution (concentration 2mg/mL) (curcumin: indocyanine green: the mass ratio of excretion body is 1:1:1), is added after mixing
Into 96 orifice plates, it is put into electroporation apparatus, according to following parameter manipulation: voltage 250V, 100 μ s of pulsewidth are spaced 1000 μ s, electric discharge time
Number 6 times.Suspension can be put into cell incubator after electroporation and be incubated for 30min, then 100,000g ultracentrifugation twice,
70min/ times, supernatant is removed, precipitating is resuspended with 200 μ L PBS and as carries curcumin/indocyanine green excretion body, curcumin packet altogether
Envelope rate is~87.87%, and indocyanine green encapsulation rate is~96.97%, as shown in Figure 2；Partial size is~200nm, as shown in Figure 3；
Zeta potential is~-15mV, as shown in Figure 4.The excretion body for the total load curcumin/indocyanine green being prepared have fluorescence at
Picture, photo-thermal effect and medicament slow release performance, such as Fig. 1, shown in 5,6.4 DEG C are protected from light storage and carry out subsequent detection and experiment.
Embodiment 5
80 μ g excretion bodies and 80 μ L curcumin solution (concentration 2mg/mL) and 40 μ L are added in 10mM PBS solution
Indocyanine green solution (concentration 2mg/mL) (curcumin: indocyanine green: the mass ratio of excretion body is 2:1:1), is added after mixing
Into 96 orifice plates, it is put into electroporation apparatus, according to following parameter manipulation: voltage 250V, 100 μ s of pulsewidth are spaced 1000 μ s, electric discharge time
Number 6 times.Suspension can be put into cell incubator after electroporation and be incubated for 30min, then 100,000g ultracentrifugation twice,
70min/ times, supernatant is removed, precipitating is resuspended with 200 μ L PBS and as carries curcumin/indocyanine green excretion body altogether.4 DEG C are protected from light storage
Deposit into row subsequent detection and experiment.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
Claims (5)
1. a kind of preparation method with diagnosis and treatment excretion body, which comprises the steps of:
1) excretion body is extracted, is purified: being filled in interstital stem cell culture solution using differential supercentrifugation from C57 mouse and is extracted this carefully
The excretion body of intracrine, obtained excretion weight are suspended from 10mM PBS solution, and -80 DEG C save backup；
2) sample preparation: the excretion body of the curcumin prepared or indocyanine green solution and step 1) is mixed in 10mM PBS, is mixed
It closes uniformly, obtains sample；
3) electricity turns: the sample of step 2) is placed in electroporation apparatus and carries out electroporation, the sample after obtaining electroporation；
4) it is incubated for: the sample of step 3) electroporation being placed in cell incubator and is protected from light incubation 30min, the liquid after being incubated for
Body；
5) it purifies: by the liquid after being incubated in step 4) with 100,000-140,000g centrifugal force 60-100min, taking precipitating
Object obtains having the function of diagnosis and treatment excretion body.
2. the preparation method with diagnosis and treatment excretion body according to claim 1, which is characterized in that the C57 mouse
Interstital stem cell culture solution is filled for no excretion body serum or without serum.
3. the preparation method with diagnosis and treatment excretion body according to claim 1, which is characterized in that in step 2), 200
0-100 μ g excretion body, 0-300 μ g curcumin or 0-300 μ g indocyanine green are separately added into 10mM PBS solution described in μ L.
4. the preparation method with diagnosis and treatment excretion body according to claim 1, which is characterized in that in step 3), electricity
The condition of perforation are as follows: voltage 0-350V, 100 μ s of pulsewidth are spaced 1000 μ s, discharge time: 0-9 times.
5. one kind has the function of diagnosis and treatment excretion body, obtained by the described in any item preparation methods of claim 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811222290.9A CN109568269B (en) | 2018-10-19 | 2018-10-19 | Exosome with diagnosis and treatment functions and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811222290.9A CN109568269B (en) | 2018-10-19 | 2018-10-19 | Exosome with diagnosis and treatment functions and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109568269A true CN109568269A (en) | 2019-04-05 |
| CN109568269B CN109568269B (en) | 2021-12-21 |
Family
ID=65920695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811222290.9A Active CN109568269B (en) | 2018-10-19 | 2018-10-19 | Exosome with diagnosis and treatment functions and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109568269B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214458A (en) * | 2020-02-27 | 2020-06-02 | 西安交通大学 | Curcuma rhizome-derived exosome-like nanoparticle and preparation method thereof |
| CN111407742A (en) * | 2020-03-30 | 2020-07-14 | 西南交通大学 | Anti-tumor nano-particles and preparation method and application thereof |
| CN113430165A (en) * | 2021-06-17 | 2021-09-24 | 山东省齐鲁细胞治疗工程技术有限公司 | THC-loaded stem cell drug delivery system and preparation method thereof |
| CN115737829A (en) * | 2022-11-23 | 2023-03-07 | 东南大学 | Photosensitive extracellular vesicle and preparation method, application and medicine thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| WO2014078768A1 (en) * | 2012-11-19 | 2014-05-22 | Troyer Deryl L | Leukocytes as delivery cells for imaging and disease therapy |
| WO2017120342A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Cellular or viral membrane coated nanostructures and uses thereof |
| CN106943432A (en) * | 2017-04-14 | 2017-07-14 | 南京盖斯夫医药科技有限公司 | A kind of excretion body in umbilical cord mesenchymal stem cells source and its application in treatment liver-cancer medicine is prepared |
| WO2018039119A1 (en) * | 2016-08-22 | 2018-03-01 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| CN108114290A (en) * | 2018-01-03 | 2018-06-05 | 东南大学 | Preparation method that is a kind of while loading chemicals and the excretion body of nano material |
| CN108159422A (en) * | 2016-12-07 | 2018-06-15 | 江西科维协同创新药物有限公司 | A kind of preparation method of self assembly drug-loading system and its compound formulation |
-
2018
- 2018-10-19 CN CN201811222290.9A patent/CN109568269B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| WO2014078768A1 (en) * | 2012-11-19 | 2014-05-22 | Troyer Deryl L | Leukocytes as delivery cells for imaging and disease therapy |
| WO2017120342A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Cellular or viral membrane coated nanostructures and uses thereof |
| WO2018039119A1 (en) * | 2016-08-22 | 2018-03-01 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| CN108159422A (en) * | 2016-12-07 | 2018-06-15 | 江西科维协同创新药物有限公司 | A kind of preparation method of self assembly drug-loading system and its compound formulation |
| CN106943432A (en) * | 2017-04-14 | 2017-07-14 | 南京盖斯夫医药科技有限公司 | A kind of excretion body in umbilical cord mesenchymal stem cells source and its application in treatment liver-cancer medicine is prepared |
| CN108114290A (en) * | 2018-01-03 | 2018-06-05 | 东南大学 | Preparation method that is a kind of while loading chemicals and the excretion body of nano material |
Non-Patent Citations (5)
| Title |
|---|
| GYEONGHUI YU等: ""Indocyanine green-incorporated exosomes for improved in vivo imaging of sentinel lymph node"", 《APPLIED BIOLOGICAL CHEMISTRY》 * |
| JIA GANG等: ""NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo"", 《BIOMATERIALS》 * |
| WANG JIE等: ""Designer Exosomes for Active Targeted Chemo-Photothermal Synergistic Tumor Therapy"", 《ADV. FUNCT. MATER》 * |
| WANG JINHENG等: ""High-throughput single-cell analysis of exosome mediated dual drugs delivery, in vivo fate and synergistic tumor therapy"", 《NANOSCALE》 * |
| 王子妤等: ""外泌体作为药物载体应用及其靶向给药策略"", 《中国细胞生物学学报》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214458A (en) * | 2020-02-27 | 2020-06-02 | 西安交通大学 | Curcuma rhizome-derived exosome-like nanoparticle and preparation method thereof |
| CN111407742A (en) * | 2020-03-30 | 2020-07-14 | 西南交通大学 | Anti-tumor nano-particles and preparation method and application thereof |
| CN111407742B (en) * | 2020-03-30 | 2021-10-22 | 西南交通大学 | Anti-tumor nano-particles and preparation method and application thereof |
| CN113430165A (en) * | 2021-06-17 | 2021-09-24 | 山东省齐鲁细胞治疗工程技术有限公司 | THC-loaded stem cell drug delivery system and preparation method thereof |
| CN113430165B (en) * | 2021-06-17 | 2022-02-08 | 山东省齐鲁细胞治疗工程技术有限公司 | THC-loaded stem cell drug delivery system and preparation method thereof |
| CN115737829A (en) * | 2022-11-23 | 2023-03-07 | 东南大学 | Photosensitive extracellular vesicle and preparation method, application and medicine thereof |
| CN115737829B (en) * | 2022-11-23 | 2024-01-30 | 东南大学 | Photosensitive extracellular vesicle, preparation method, application and medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109568269B (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109568269A (en) | One kind having the function of diagnosis and treatment excretion body and preparation method thereof | |
| Chen et al. | Microfluidic electrospray niacin metal-organic frameworks encapsulated microcapsules for wound healing | |
| CN108114290A (en) | Preparation method that is a kind of while loading chemicals and the excretion body of nano material | |
| Li et al. | Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post‐Photothermal Therapy | |
| CN108671231B (en) | Multifunctional nano-carrier for tumor photothermal synergistic treatment and ultrasonic imaging and preparation method thereof | |
| CN112121029B (en) | Bionic dopamine polymerization drug-loaded nano delivery system and preparation method thereof | |
| Wu et al. | Immunomodulation of tumor microenvironment by arginine-loaded iron oxide nanoparticles for gaseous immunotherapy | |
| CN103961712B (en) | A kind of superparamagnetic Fe 3 O 4 nano-particles pharmaceutical carrier and its preparation method and application | |
| CN104288784B (en) | Nanometer hydroxyapatite genomic medicine compound and preparation method and application | |
| CN105797157B (en) | A kind of preparation method and application of porous nucleocapsid bimetallic organic frame nano drug-carrying body | |
| CN104043135A (en) | Albumin indocyanine green paclitaxel compound as well as preparation method and application thereof | |
| CN109666695A (en) | A kind of excretion body carrier and its preparation method and application of targeted integration element α v β 3 | |
| Zheng et al. | Targeted delivery of tungsten oxide nanoparticles for multifunctional anti-tumor therapy via macrophages | |
| CN105982844A (en) | Resveratrol lipidosome gel and preparation method thereof | |
| Peng et al. | Silicon nanostructures for cancer diagnosis and therapy | |
| Wang et al. | Synthesis of Janus Au nanorods/polydivinylbenzene hybrid nanoparticles for chemo-photothermal therapy | |
| Chen et al. | Nanoengineered biomimetic Cu-based nanoparticles for multifunational and efficient tumor treatment | |
| CN114259477A (en) | Nano delivery system capable of promoting penetration, relieving tumor hypoxia and targeting tumor cells, and preparation method and application thereof | |
| CN106512027A (en) | Ferroferric oxide/chitosan/indocyanine green composite particles and preparation method and application thereof | |
| CN112791061B (en) | Preparation method of multi-stage bionic nano-drug carrier with targeting long circulation | |
| Cheng et al. | Redox‐Responsive Nanoparticles with Aggregation‐Induced Emission (AIE) Characteristic for Fluorescence Imaging | |
| CN112755185A (en) | Polydopamine-coated drug-loaded molybdenum disulfide nanosheet and preparation and application thereof | |
| CN115192708B (en) | Nanocomposite loaded with antitumor drug, nano drug-carrying system, preparation and application | |
| CN110755607A (en) | Zinc oxide and antigen co-drug-loaded nano vaccine, and preparation method and application thereof | |
| CN109851799A (en) | A kind of c (RGDfk) cyclic peptide-chitosan stearic acid grafting carrier micelle and preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xie Maobin Inventor after: Li Guangmeng Inventor after: Wang Jinheng Inventor before: Xie Maobin Inventor before: Li Guangmeng |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230825 Address after: Unit 302, 3rd Floor, No. 6 Spiral Third Road, Guangzhou International Biological Island, Huangpu District, Guangzhou City, Guangdong Province, 510000 Patentee after: Green Key Biotechnology (Guangzhou) Co.,Ltd. Address before: No. 195, Dongfeng West Road, Yuexiu District, Guangzhou, Guangdong 510180 Patentee before: GUANGZHOU MEDICAL University |
|
| TR01 | Transfer of patent right |